Controlled delivery formulations remain one of the favored tools for advancing the lifecycle of pharmaceutical products. A traditional strategy is to initially launch multiple daily doses of an immediate-release (IR) product, then reformulate into a once-daily modified-release product, simplifying dosing regimens while retaining efficacy and potentially improving its safety profile.
Further, excipients have become major research components in the pharmaceutical industry. Controlled release excipients give the formulator the ability to carry APIs to a targeted location in the body. This benefit increases the product’s bioavailability and minimizes side effects. With the correct excipient, formulators can control when, where, and how an API is released.
Excipient Selection Challenges
Given the lack of an approval pathway, many drug developers are hesitant to take on the responsibility of toxicology and clinical trials with a untested materials, which may run risk jeopardizing approval of their new drug applications. Additionally, for certain patient populations, excipient choices are somewhat limited. However, there has been a growth in excipient suppliers developing novel excipients that may provide solutions and support to move existing formulations into new areas.
Rational Excipient Selection & Collaboration
Many new excipients are modifications or combinations of previously approved excipients. Excipient selection for the formulation for an immediate release tablet is typically guided by a number of critical attributes of the active ingredient, including concentration, compactability, and solubility.
Excipient manufacturers are working closer with drug product manufacturers as early as possible in the drug product development process in order to not only identify the issues, but to mitigate the impact of the issues proactively. The most successful controlled release formulation approaches have been where excipient suppliers have worked side-by-side with drug developers to understand their specific needs, and, over time, have developed new solutions to meet controlled release formulation challenges as they have arisen.
Interested in Learning More?
Consider joining us in Philadelphia, PA this November (27-29th November, 2018) at the 2018 Controlled & Modified Drug Release Summit and learn 2 years worth of new product development strategies in just 2 days! This industry-leading event will bring together key decision makers and innovators within this rapidly growing space. By attending this unique event, you will learn directly from industry’s leading experts and hear unique case study sessions and take-home examples to enhance your product pipeline. Gather insights into the latest technologies and methods in improving drug release mechanisms, maximizing exposure, and reducing time-to-market. Additionally, this must-attend event will showcase the latest regulatory guidance updates and the implications for the industry.
Why Consider Attending the 2018 Controlled & Modified Drug Release Summit?
- 45+ industry-led speaker faculty over 2 full days sharing innovative drug development take-home strategies
- 12+ hours of networking sessions and breaks over two full days to learn from network with pharmaceutical and biotech senior formulation, development and delivery professionals
- 160+ Senior Participants spanning pharma, biotech and specialty delivery & technology companies
- Dynamic Tech Showcase Hall with multiple leading formulation development, excipient suppliers, delivery and modeling experts
- 2 Events in One! Co-located and shared tech showcase with the 3rd Peptide Drug Design & Delivery Summit
Benefit from industry participation from Pfizer, Merck, Novartis, Bristol Myers Squibb, GlaxoSmithKline, Celgene, Johnson & Johnson, and many more controlled and modified drug release innovators. Consider joining us in Philadelphia this November to enhance your drug delivery and formulation capabilities, which will decrease time to market on your drug products. Planning to attend? Register before 5PM ET Friday, September 28, 2018 and save $200 (early-bird pricing).